NGNE

Neurogene Inc. (NGNE) | Rumor.io

Neurogene

NGNE

Attention (50-day avg)0%

Attention rank (50-day avg)#3,175

Bullish sentiment (50-day avg)100%

Price to earnings ratio-6.72

Market capitalization569.9M

Earnings per share-5.04

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-90.4M

Social

What share of all stock conversation is about NGNE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Feb 27

Neurogene Inc. ($NGNE) has received FDA Breakthrough Therapy Designation for NGN-401 gene therapy for Rett syndrome, based on interim Phase 1/2 data showing clinically meaningful and sustained improvements.
The Embolden registrational clinical trial for NGN-401 is on track to complete dosing in Q2 2026, with the Breakthrough Therapy Designation expected to accelerate the development process.
The stock price of $NGNE has rallied significantly, with some analysts setting a $200 price target, driven by the potential of NGN-401 to treat Rett syndrome.

Generated by AI

Sentiment

Of the messages about NGNE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	97.84% +15.38
Bearish	—	—	—	2.16% -15.38

Feb 27

Neurogene Inc. (NGNE) receives FDA Breakthrough Therapy Designation for NGN-401, a gene therapy for Rett syndrome, based on interim Phase 1/2 data showing clinically meaningful and durable improvements.
The Breakthrough Therapy Designation strengthens NGNE's intellectual property moat and de-risks its clinical pathway, making it a major regulatory catalyst.
NGNE's stock price surges to $25.76, up 30.89%, with analysts issuing bullish ratings and price targets, including a $200 target from Canaccord and a "strong buy" consensus rating.

Generated by AI

Topics

Of the messages about NGNE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	77.57%
Earnings	—	—	—	0.5%
Analysts	—	—	—	7.81%
Controversies	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	14.12%

Announcements· Feb 27

Neurogene Inc. ($NGNE) received FDA Breakthrough Therapy Designation for its gene therapy, NGN-401, for the treatment of Rett syndrome.
The designation is based on interim Phase 1/2 data showing clinically meaningful and durable improvements across multiple functional domains in patients with Rett syndrome.
The Breakthrough Therapy Designation is expected to accelerate the development and review process for NGN-401, potentially positioning it as a best-in-class gene therapy for Rett syndrome.

Technical Analysis· Feb 27

Key resistance is overhead for $NGNE, requiring volume to push through.
$NGNE is primed for another leg higher, with buyers still pressing and a trend that may not be done yet.
Technical breakout confirmed for $NGNE, clearing $21.75 resistance on high volume, with a target of $33.87 and catalyst of FDA Breakthrough Therapy news.

Generated by AI

Community

Of the messages about NGNE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	29.83%
Newcomers	—	—	100%	70.17%

Feb 27

The FDA has granted Breakthrough Therapy Designation to Neurogene Inc.'s NGN-401 gene therapy for Rett syndrome, based on interim Phase 1/2 data showing clinically meaningful and durable improvements across multiple functional domains.
The Embolden registrational clinical trial is currently being evaluated, with completion of dosing expected in Q2 2026, and Neurogene is on track to complete dosing in the trial.
The stock price of Neurogene Inc. has surged to $26.11, a +32.67% increase, as aggressive buyers overwhelm sellers, fueled by the FDA's Breakthrough Therapy Designation for NGN-401.

Generated by AI

NEW YORK, September 08, 2026--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that Company management will participate in the H.C. Wainwright 28th Annual Global Investment Conference.

22d agoYahoo Finance

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK, September 04, 2026--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 38,330 shares of the Company’s common stock to two new employees (the "Inducement Grants") on September 1, 2026 (the "Grant Date"). The In

26d agoYahoo Finance

Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Cardiff Oncology (CRDF)

Detailed price information for Neurogene Inc (NGNE-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Neurogene stock price target lowered to $65 by H.C. Wainwright

1mo agoInvesting.com

Canaccord lowers Neurogene stock price target on valuation review

1mo agoInvesting.com

Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates

1mo agoca.finance.yahoo.com

Also Discussed

Investors talking about NGNE also mention

#	Name	Attention
1	Taysha Gene Therapies, Inc.TSHA	0%0
2	Palvella Therapeutics, Inc.PVLA	0%new
3	Bushido Capital US Equity ETFSMRI	0%0
4	Mineralys Therapeutics, Inc.MLYS	0%+0
5	Monarch Casino & Resort, Inc.MCRI	0%0
6	Cogent Biosciences, Inc.COGT	0%+0
7	BG Staffing IncBGSF	0%new
8	Janux Therapeutics, Inc.JANX	0%0
9	Flexible Solutions International Inc.FSI	0%0
10	AIFU Inc. Class A Ordinary ShareAIFU	0%+0

Neurogene Inc.

Healthcare
Biotechnology

Neurogene Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for rare neurological diseases. Its current pipeline centers on gene therapy programs designed to address severe disorders such as Rett syndrome and CLN5 Batten disease, with candidates that use adeno-associated virus delivery and proprietary transgene regulation technology to control gene expression in the central nervous system. Neurogene’s work is aimed at treating conditions with significant unmet medical need, where conventional approaches have limited impact on the underlying cause of disease. The company also operates gene therapy manufacturing capabilities to support clinical development and production of its programs. Headquartered in New York, Neurogene Inc. is part of the broader biotechnology and rare-disease therapeutics market, where it contributes to the advancement of precision genetic medicine for devastating neurological disorders.

Website

Location

535 W 24th Street

New York, NY, 10011

United States

Social

What share of all stock conversation is about NGNE?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Feb 27

Neurogene Inc. ($NGNE) has received FDA Breakthrough Therapy Designation for NGN-401 gene therapy for Rett syndrome, based on interim Phase 1/2 data showing clinically meaningful and sustained improvements.
The Embolden registrational clinical trial for NGN-401 is on track to complete dosing in Q2 2026, with the Breakthrough Therapy Designation expected to accelerate the development process.
The stock price of $NGNE has rallied significantly, with some analysts setting a $200 price target, driven by the potential of NGN-401 to treat Rett syndrome.

Generated by AI

Sentiment

Of the messages about NGNE that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	97.84% +15.38
Bearish	—	—	—	2.16% -15.38

Feb 27

Neurogene Inc. (NGNE) receives FDA Breakthrough Therapy Designation for NGN-401, a gene therapy for Rett syndrome, based on interim Phase 1/2 data showing clinically meaningful and durable improvements.
The Breakthrough Therapy Designation strengthens NGNE's intellectual property moat and de-risks its clinical pathway, making it a major regulatory catalyst.
NGNE's stock price surges to $25.76, up 30.89%, with analysts issuing bullish ratings and price targets, including a $200 target from Canaccord and a "strong buy" consensus rating.

Generated by AI

Topics

Of the messages about NGNE that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	77.57%
Earnings	—	—	—	0.5%
Analysts	—	—	—	7.81%
Controversies	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	14.12%

Announcements· Feb 27

Neurogene Inc. ($NGNE) received FDA Breakthrough Therapy Designation for its gene therapy, NGN-401, for the treatment of Rett syndrome.
The designation is based on interim Phase 1/2 data showing clinically meaningful and durable improvements across multiple functional domains in patients with Rett syndrome.
The Breakthrough Therapy Designation is expected to accelerate the development and review process for NGN-401, potentially positioning it as a best-in-class gene therapy for Rett syndrome.

Technical Analysis· Feb 27

Key resistance is overhead for $NGNE, requiring volume to push through.
$NGNE is primed for another leg higher, with buyers still pressing and a trend that may not be done yet.
Technical breakout confirmed for $NGNE, clearing $21.75 resistance on high volume, with a target of $33.87 and catalyst of FDA Breakthrough Therapy news.

Generated by AI

Community

Of the messages about NGNE, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	29.83%
Newcomers	—	—	100%	70.17%

Feb 27

The FDA has granted Breakthrough Therapy Designation to Neurogene Inc.'s NGN-401 gene therapy for Rett syndrome, based on interim Phase 1/2 data showing clinically meaningful and durable improvements across multiple functional domains.
The Embolden registrational clinical trial is currently being evaluated, with completion of dosing expected in Q2 2026, and Neurogene is on track to complete dosing in the trial.
The stock price of Neurogene Inc. has surged to $26.11, a +32.67% increase, as aggressive buyers overwhelm sellers, fueled by the FDA's Breakthrough Therapy Designation for NGN-401.

Generated by AI

Neurogene

Social

Feb 27

Sentiment

Feb 27

Topics

Announcements· Feb 27

Technical Analysis· Feb 27

Community

Feb 27

News

Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Cardiff Oncology (CRDF)

Neurogene stock price target lowered to $65 by H.C. Wainwright

Canaccord lowers Neurogene stock price target on valuation review

Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates

Also Discussed

Neurogene Inc.

Company Information

Location

News

Neurogene to Participate in H.C. Wainwright 28th Annual Global Investment Conference

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Cardiff Oncology (CRDF)

Neurogene stock price target lowered to $65 by H.C. Wainwright

Canaccord lowers Neurogene stock price target on valuation review

Neurogene Reports Second Quarter 2026 Financial Results and Highlights Recent Updates

Also Discussed

Social

Feb 27

Sentiment

Feb 27

Topics

Announcements· Feb 27

Technical Analysis· Feb 27

Community

Feb 27